Chief Commercial Officer · ARS Pharmaceuticals, Inc. · ARS Pharmaceuticals, Inc. — Stock Option (right to buy)
Side
A
Value
—
Shares
1.00M
Price
—
Executed
Sep 1, 2026
Disclosed
Sep 2, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 1 executedSep 2, 2026 disclosed
SPRY · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
ARS Pharmaceuticals, Inc. — Stock Option (right to buy)
Ticker
SPRY
Shares
1.00M
Price per share
$0
Execution date (reported)
Sep 1, 2026
Owned after transaction
1.00M shares
Days from execution to publication
1
What this establishes
Smith Margaret Ekins filed this Form 4 reporting a grant or award of SPRY on Sep 1, 2026. It became public on Sep 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Commercial Officer
Smith Margaret Ekinscik:0002149973
Issuer
ARS Pharmaceuticals, Inc.cik:0001671858
Revision history · 0
No field has changed since this record was first ingested.
